7.40
0.40 (5.71%)
| Penutupan Terdahulu | 7.00 |
| Buka | 6.97 |
| Jumlah Dagangan | 1,719,058 |
| Purata Dagangan (3B) | 1,362,301 |
| Modal Pasaran | 598,666,944 |
| Harga / Pendapatan (P/E Ke hadapan) | 6.60 |
| Harga / Jualan (P/S) | 2.28 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2026 |
| Margin Operasi (TTM) | -276.53% |
| EPS Cair (TTM) | -5.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1,391.60% |
| Nisbah Semasa (MRQ) | 3.58 |
| Aliran Tunai Operasi (OCF TTM) | -282.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -201.84 M |
| Pulangan Atas Aset (ROA TTM) | -55.01% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Phathom Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 2.5 |
| AI Insight | NA |
| Purata | 0.50 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.28% |
| % Dimiliki oleh Institusi | 84.77% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 30 Jun 2026 | 7,464,572 |
| Carlyle Group Inc. | 30 Jun 2026 | 3,496,808 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |